Safety and efficacy of long-shelf-life allogeneic adipose-derived mesenchymal stem cell line-derived platelet-like cells for refractory foot ulcers: A translational preclinical and phase 1/2a study
ASCL-PLCs are safe and a promising therapeutic option for refractory ulcers and can potentially reduce amputation rates, improve patient outcomes, and minimize the socioeconomic impact due to chronic wounds. Their long shelf life and cryopreservation stability make wound management practical and accessible. Moreover, their efficacy with simple topical application suggests a minimally invasive strategy suitable for outpatient care. Further large-scale trials are recommended.This study was registered with the Japan Registry of Clinical Trials (jRCT ID: jRCTa030200053; on June 18, 2020, https://jrct.mhlw.go.jp/en-latest-detail/jRCTa030200053).
Authors
- Masaki Yazawa (ORCID: https://orcid.org/0000-0002-2446-2766)
- Yasunori Sato (ORCID: https://orcid.org/0000-0002-7189-5126)
- Yukako Ono‐Uruga
- Naoki Fujimura (ORCID: https://orcid.org/0000-0001-8714-7723)
- Jun Okui (ORCID: https://orcid.org/0000-0002-5226-1347)
- Hideaki Obara
- Yuko Kitagawa (ORCID: https://orcid.org/0000-0002-0271-5670)
- Kentaro Matsubara (ORCID: https://orcid.org/0000-0002-6438-6040)
- Yumiko Matsubara
Institutions
- Keio University (JP)
- Keio University Hospital (JP)
- Shibuya (Japan) (JP)
Publication Details
- Journal
- Regenerative Therapy
- Published
- 2025-08-14
- DOI
- https://doi.org/10.1016/j.reth.2025.08.006
- Primary Topic
- Diabetic Foot Ulcer Assessment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00